Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Completed · Phase 3 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of DVS SR (25 and 50 mg/day) in the treatment of adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.

Key facts

Study ID

NCT00798707

Run by

Pfizer

People needed

709

Starts

2008-12-01

Expected to finish

2010-04-01

Last updated by the study team

2011-06-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)
• Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of >= 20
• Clinical Global Impressions Scale-Severity (CGI-S) score of >= 4

You may not qualify if…

• Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline
• Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

Where it is running

• Pfizer Investigational Site — Beverly Hills, California, United States
• Pfizer Investigational Site — Cerritos, California, United States
• Pfizer Investigational Site — Garden Grove, California, United States
• Pfizer Investigational Site — Los Alamitos, California, United States
• Pfizer Investigational Site — St. Petersburg, Florida, United States
• Pfizer Investigational Site — Atlanta, Georgia, United States
• Pfizer Investigational Site — Smyrna, Georgia, United States
• Pfizer Investigational Site — Libertyville, Illinois, United States
• Pfizer Investigational Site — Dayton, Ohio, United States
• Pfizer Investigational Site — East Providence, Rhode Island, United States
• Pfizer Investigational Site — Columbia, South Carolina, United States
• Pfizer Investigational Site — Memphis, Tennessee, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — San Antonio, Texas, United States
• Pfizer Investigational Site — Salt Lake City, Utah, United States
• Pfizer Investigational Site — Kirkland, Washington, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — Brown Deer, Wisconsin, United States
• Pfizer Investigational Site — Nagoya, Aichi-ken, Japan
• Pfizer Investigational Site — Toyoake, Aichi-ken, Japan
• Pfizer Investigational Site — Noda, Chiba, Japan
• Pfizer Investigational Site — Fukuoka, Fukuoka, Japan
• Pfizer Investigational Site — Fukuoka, Fukuoka, Japan
• Pfizer Investigational Site — Kitakyushu, Fukuoka, Japan
• Pfizer Investigational Site — Arcadia, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.